 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12345678910111213...123124» |
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Clinical, Retrospective data, Journal, Real-world evidence, Real-world: Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort. (Pubmed Central) - Nov 4, 2024
The increased risk of hepatic decompensation in patients treated with AZ/BV who have impaired baseline liver function underscores the need for careful monitoring. Future trials should aim to distinguish more clearly between metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies. (Pubmed Central) - Nov 3, 2024
Tumor-bearing mouse experiments demonstrated that bergamottin (BGM), a competitive inhibitor of CYP1A1, can enhance the efficacy of both lenvatinib and combination therapy. Our research revealed one mechanism by which hepatoma cells can survive the combination therapy, providing a theoretical basis for the refined treatment of HCC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Outcome of metastatic, radioactive-iodine refractory differentiated, medullary and anaplastic thyroid carcinoma (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_344;
Our research revealed one mechanism by which hepatoma cells can survive the combination therapy, providing a theoretical basis for the refined treatment of HCC. Our study showed real world data of patients with RAIR DTC, metastatic medullary TC, and anaplastic TC with promising real-world response rate to lenvatinib, redifferentiation therapy, RET inhibitors, long-term response to BRAF & MEK inhibitor combination and immunotherapy with lenvatinib combination.
- Jemperli (dostarlimab-gxly) / GSK
Post-Progression Survival Outcomes in Patients with Primary Advanced or Recurrent Endometrial Cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial Who Received Follow-up Immunotherapy (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_80;
P3
Aims: In Part 1 of the phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796; funding: GSK), dostarlimab+carboplatin-paclitaxel (CP) significantly improved PFS (HR 0.64) and OS (HR 0.69) vs placebo+CP in the overall population of patients with pA/rEC...At interim analysis 2 (37.2 mo of follow-up), updated post hoc analyses of OS adjusted for treatment switching via rank-preserving structural failure time (RPSFT) were performed in the overall and MMRp/MSS populations of pts who received FUACT of IO and for patients receiving pembrolizumab-lenvatinib (PEM-LEN) in the MMRp/MSS population... Adjusted OS using RPSFT for subsequent use of IO in the overall and MMRp/MSS populations, including PEM-LEN in the MMRp/MSS population, showed limited impact on survival benefits, supporting frontline use of dostarlimab+CP as standard of care in all patients with pA/rEC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
A Phase Ib/II trial of Lenvatinib plus Pembrolizumab plus Fulvestrant in ER+/HER2- Metastatic Breast Cancer (MBC) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1686;
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_865;
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 1, 2024
P3, N=1069, Active, not recruiting, Sponsor: Eisai Inc.
Adjusted OS using RPSFT for subsequent use of IO in the overall and MMRp/MSS populations, including PEM-LEN in the MMRp/MSS population, showed limited impact on survival benefits, supporting frontline use of dostarlimab+CP as standard of care in all patients with pA/rEC. Trial completion date: Jul 2024 --> Mar 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment (clinicaltrials.gov) - Oct 31, 2024
P2, N=35, Not yet recruiting, Sponsor: University of Chicago
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis. (Pubmed Central) - Oct 30, 2024
Addition of lenvatinib to transarterial chemoembolization improves OS, PFS, ORR, and DCR for patients with intermediate-stage hepatocellular carcinoma beyond the up-to-seven criteria. This combination therapy is a superior treatment option for intermediate-stage hepatocellular carcinoma patients with high tumor burden.
- Combination of LND101, a healthy donor microbiome transplantation product, to doublet immunotherapy or immunotherapy combined with targeted therapy in metastatic renal cell carcinoma patients (Exhibit Halls AB - George R. Brown Convention Center) - Oct 30, 2024 - Abstract #SITC2024SITC_1926;
P1
Finally, our results suggest that LND101 added to ICI-based combination therapy as 1L in mRCC may improve clinical outcomes. Ethics Approval Ethics number: 114962.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. (Pubmed Central) - Oct 30, 2024
Compared to RT + S, RT + L had good efficacy in the treatment of hepatocellular carcinoma with PVTT. Validation is needed in prospective studies with larger sample sizes.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report. (Pubmed Central) - Oct 30, 2024
To date, this patient continues to show a near complete response to this treatment regimen. To our knowledge, this is the first documented case of SMARCB1-deficient RMC without hemoglobinopathy to receive this treatment regimen and show such a response.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Metastases: Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. (Pubmed Central) - Oct 30, 2024
To our knowledge, this is the first documented case of SMARCB1-deficient RMC without hemoglobinopathy to receive this treatment regimen and show such a response. BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Multidisciplinary approaches in the management of advanced hepatocellular carcinoma: Exploring future directions. (Pubmed Central) - Oct 30, 2024
This case report demonstrated the efficacy of the combination therapy of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, epclusa, lenvatinib and sintilimab for a patient with advanced HCC, and the report can serve as a reference for clinical practice. We would also like to share some of our views.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report. (Pubmed Central) - Oct 30, 2024
We would also like to share some of our views. PDOs for drug sensitivity contribute to screening effective chemotherapy drugs for advanced pCCA, promoting conversion therapy and improving the prognosis.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy: Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach. (Pubmed Central) - Oct 30, 2024
We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma. Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer, but the combination of all three therapeutic approaches needs more research.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical data, Journal: Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy. (Pubmed Central) - Oct 30, 2024
If, following downstaging, the patient qualifies for liver resection based on locally prevalent resectability criteria, then such therapy is labelled as conversion (from unresectable to resectable) therapy. In unresectable patients treated by a combination of treatment options, serological markers like neutrophil-to-lymphocyte ratio and alpha-fetoprotein are reported to predict treatment responses, thus enabling personalized medicine.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Review, Journal, IO biomarker: Systemic treatments for radioiodine-refractory thyroid cancers. (Pubmed Central) - Oct 30, 2024
Due to DTCs' distinctive radioiodine (RAI) uptake mechanism, standard treatment involving surgery, with or without adjunctive therapy using RAI and levothyroxine inhibition, typically yields favorable prognoses for the majority of patients with DTCs...Lenvatinib and sorafenib, multi-kinase inhibitors, represent the standard first-line systemic treatment options, while cabozantinib is the standard second-line treatment option, for this purpose...However, further validation through multicenter, large-sample, double-blinded randomized controlled trials are essential. Enhanced treatment strategies and innovative therapies are expected to benefit a broader spectrum of patients as these advancements progress.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Real-world evidence, Surgery, Real-world: Prognosis of Neoadjuvant HAIC and Lenvatinib Followed by Surgery versus Direct Resection for Resectable or Borderline Resectable Hepatocellular Carcinoma: A Real-World Study. (Pubmed Central) - Oct 29, 2024
Treatment-related grade ?3 adverse events were comparable between the two groups. For patients with resectable or marginally resectable HCC in the intermediate to advanced stages of BCLC, surgery after neoadjuvant HAIC+Len may offer improved long-term prognosis.
- ||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Oct 28, 2024
P3, N=480, Completed, Sponsor: Merck Sharp & Dohme LLC
For patients with resectable or marginally resectable HCC in the intermediate to advanced stages of BCLC, surgery after neoadjuvant HAIC+Len may offer improved long-term prognosis. Active, not recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A-Mediated Endolysosomal Trafficking and Degradation of EGFR. (Pubmed Central) - Oct 28, 2024
Notably, overexpression of TBC1D31 markedly increases the resistance of HCC cells to lenvatinib, whereas inhibition of the TBC1D31-EGFR axis can reverse this resistance phenotype. This study highlights that TBC1D31 at 8q24.13 is a new critical oncogene, uncovers a novel mechanism of EGFR activation in HCC, and proposes the potential strategies for treating HCC patients with TBC1D31 amplification or overexpression.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Enrollment change, Trial primary completion date, IO biomarker, Metastases: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma (clinicaltrials.gov) - Oct 27, 2024
P=N/A, N=80, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
This study highlights that TBC1D31 at 8q24.13 is a new critical oncogene, uncovers a novel mechanism of EGFR activation in HCC, and proposes the potential strategies for treating HCC patients with TBC1D31 amplification or overexpression. N=120 --> 80 | Trial primary completion date: Jan 2024 --> May 2024
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Solitary Cardiac Metastasis of Hepatocellular Carcinoma. (Pubmed Central) - Oct 27, 2024
N=120 --> 80 | Trial primary completion date: Jan 2024 --> May 2024 No abstract available
- || Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P1/2 data, Journal, Metastases: Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE). (Pubmed Central) - Oct 27, 2024
No abstract available Nivolumab plus lenvatinib had a manageable safety in advanced BTC, but its efficacy in the second-line treatment was limited.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal, Real-world evidence, Real-world: Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. (Pubmed Central) - Oct 26, 2024
OS trends in the White, Black, and Hispanic patient cohorts were consistent with that of the overall population. Atezolizumab plus bevacizumab was associated with improved survival outcomes compared with sorafenib and lenvatinib in patients with uHCC, both overall and across racial and ethnic subgroups.
- | Journal, Real-world evidence, Real-world: Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. (Pubmed Central) - Oct 26, 2024
Atezolizumab plus bevacizumab was associated with improved survival outcomes compared with sorafenib and lenvatinib in patients with uHCC, both overall and across racial and ethnic subgroups. Our findings suggest that L+P and A+B exhibit comparable efficacy and safety profiles in real-world settings.
- ||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Adverse events, Metastases: Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients. (Pubmed Central) - Oct 26, 2024
The estimated costs of managing VEGFR TKI class-effect AEs were lowest with tivozanib, and highest with lenvatinib and everolimus, indicating potentially differential healthcare resource burden by TKI regimen. The use of tivozanib in the 3
- | Journal, Metastases, Immuno-oncology: Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era. (Pubmed Central) - Oct 26, 2024
The implementation of IO therapy was significantly associated with longer survival in the nccRCC population. Further studies are needed to establish a more effective treatment strategy in this population using multiple regimens of IO combination therapy.
- ||| E7386 / Eisai, PRISM Pharma
Trial completion: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Oct 24, 2024
P1/2, N=89, Completed, Sponsor: Eisai Inc.
Further studies are needed to establish a more effective treatment strategy in this population using multiple regimens of IO combination therapy. Active, not recruiting --> Completed
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective ,single-arm, phase 2 study (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_332;
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Interim results of Neoadjuvant TACE Plus Lenvatinib and Tislelizumab in Resectable HCC at CNLC Stages IB and IIA with High-risk of recurrence: A Prospective, Single-Arm, Phase II Trial (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_330;
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma: A Single-arm, Phase II Study (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_329;
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_303;
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_299;
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Machine learning radiomics based on CT to predict response to lenvatinib plus Tislelizumab based therapy for unresectable hepatocellular carcinoma (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_243;
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Combination therapy, Metastases: Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-analysis. (Pubmed Central) - Oct 23, 2024
Lenvatinib significantly enhances survival outcomes in metastatic RCC patients compared with other TKIs. While associated with various adverse events, its safety profile is comparable to other TKIs.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. (Pubmed Central) - Oct 22, 2024
Grade 3-5 treatment-related adverse events were documented in 48.7% (pembrolizumab/lenvatinib) and 75.6% (CC) of patients (p=0.034), which led to treatment discontinuation in 10.3% and 17.8% of cases, respectively. This is the first comparative study in patients with metastatic melanoma refractory to PD-1/CTLA-4 inhibition and showed significantly longer outcomes in cases treated with pembrolizumab/lenvatinib versus CC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker, Surgery: Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. (Pubmed Central) - Oct 22, 2024
Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC)...The presence of MPR or pCR could improve prognosis in patients with initially uHCC who underwent conversion surgery following triple therapy. The PR may become a surrogate marker for predicting the prognosis of these patients.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
P3 data, Journal: Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. (Pubmed Central) - Oct 22, 2024
Responses were seen even in those patients with more severe disease at baseline. Tumor responses occurred early and were durable.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Correspondence on letter to the editor regarding "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma". (Pubmed Central) - Oct 21, 2024
Tumor responses occurred early and were durable. No abstract available
- | Vonjo (pacritinib) / SOBI, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1. (Pubmed Central) - Oct 19, 2024
Immunohistochemical analysis of tumor sections revealed that pacritinib reduced Ki67 staining and phosphorylated IRAK1. Our findings suggest that pacritinib may be a promising therapeutic option for the treatment of advanced HCC, particularly in patients who have developed resistance to lenvatinib.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models. (Pubmed Central) - Oct 19, 2024
The compounds were tested against human hepatocellular carcinoma (HCC), human colon adenocarcinoma and human gastric carcinoma cell lines. With favorable pharmacokinetics profiles, compounds 12 and compound 14 were selected for in vivo efficacy studies in Hep3B mice models and demonstrated efficacious than sorafenib.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy. (Pubmed Central) - Oct 18, 2024
The multivariate analysis showed that the abundance of Bacteroides_AF20_13LB and Ruminococcus_ AF25_28AC was independent related factors for PFS, and the abundance of Bacteroides_AF20_13LB was an independent related factor of OS. The enrichment of specific gut microbiota affected clinical efficacy and survival benefits in HCC treated with anti-PD-1 therapy and may be a promising non-invasive gut microbial biomarker and a new strategy for modulating immunotherapy in HCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, New trial, Metastases: Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab (clinicaltrials.gov) - Oct 17, 2024
P=N/A, N=100, Recruiting, Sponsor: CHA University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: MA-ICC-II-006: Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF (clinicaltrials.gov) - Oct 17, 2024
P2, N=68, Not yet recruiting, Sponsor: Harbin Medical University
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review). (Pubmed Central) - Oct 17, 2024
In addition, the superiority of LEN combination therapy has been shown to potentially overcome the limitations of LEN monotherapy in a series of research, and a range of promising indicators for predicting treatment response and prognosis have been discovered in recent years. In this review, we summarize the latest developments in LEN resistance, the efficacy and safety of LEN combination therapy as well as associated indicators, which may provide new insight into its resistance as well as ideas in the treatment of advanced HCC.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study. (Pubmed Central) - Oct 16, 2024
Subgroup analysis showed that for patients with a maximum tumor diameter greater than 7 cm, AFP > 400 ng/ml and accompanied by portal vein tumor thrombus, and Child-Pugh class A, there was a statistically significant difference in OS between TLT and TL groups. OS and PFS were significantly improved in patients who received TLT compared to those who received TL, patients with a largest tumor diameter greater than 7 cm, AFP > 400 ng/ml, Child-Pugh class A and PVTT appeared to derive more benefit.
- | Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: CCGLC-013: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Oct 16, 2024
P2, N=36, Recruiting, Sponsor: Tongji Hospital
OS and PFS were significantly improved in patients who received TLT compared to those who received TL, patients with a largest tumor diameter greater than 7 cm, AFP > 400 ng/ml, Child-Pugh class A and PVTT appeared to derive more benefit. Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: CCGLC-011: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 16, 2024
P2, N=36, Recruiting, Sponsor: Tongji Hospital
Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2026 Trial completion date: Jun 2026 --> Jun 2027
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) (clinicaltrials.gov) - Oct 16, 2024
P=N/A, N=15, Not yet recruiting, Sponsor: Fujian Provincial Hospital